Bisfosfonaattien vaikutus luuntiheyteen ja luun uusiutumiseen leikkauksen jälkeen primaarissa hyperparatyreoosissa. - PHPT ja osteoporoosi

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2008-005405-20-FI

Enrollment

Registered

2008-09-24

Start date

2008-12-05

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Potilailla on primaari hyperparatyreoosi ja osteoporoosi. Hyperparatyreoosin hoidoksi on suunniteltu leikkaushoitoa. MedDRA version: 9.1 Level: LLT Classification code 10020707 Term: Hyperparathyroidism primary

Interventions

Trade Name: Aclasta Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ZOLEDRONIC ACID CAS Number: 118072938 Pharmaceutical form of the placebo: Solution for infusion Rout

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Finland

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026